SCHEMBL6295067

SCHEMBL6295067

CN1CCc2ccc(NC(=O)c3ccc(C(F)(F)F)cc3F)cc2C1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 4/20 0.53
TRPV4 Q9HBA0 1/20 0.52
GPR27 Q9NS67 1/20 0.47
NPC1 O15118 1/20 0.47
TP53 P04637 1/20 0.47
MAPT P10636 1/20 0.47
NFKB1 P19838 1/20 0.47
HTT P42858 1/20 0.47
RAB9A P51151 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
SLC6A9 P48067 1/20 0.46
DDR1 Q08345 1/20 0.45
DDR2 Q16832 1/20 0.45
CPT2 P23786 1/20 0.45
CPT1A P50416 1/20 0.45
CPT1B Q92523 1/20 0.45
SMO Q99835 1/20 0.44
PTGDR2 Q9Y5Y4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6294844 0.86 NPC1 (0.54) NPC1TP53MAPTNFKB1HTT
SCHEMBL6295057 0.82 DDR1 (0.59) NPC1TP53MAPTRAB9ASMN1; SMN2
SCHEMBL8135393 0.82 EPHX2 (0.59) EPHX2NPC1RAB9A
SCHEMBL6293640 0.81 MEN1 (0.57) MAPTHTTRAB9A
SCHEMBL6293966 0.80 DDR1 (0.56) NPC1TP53NFKB1HTTRAB9A
SCHEMBL495719 0.80 TRPV1 (0.61) EPHX2TRPV4GPR27
SCHEMBL7792074 0.79 ROCK2 (0.51) NPC1TP53MAPTRAB9AALDH1A1
SCHEMBL8118160 0.79 KMT2A (0.56) EPHX2NPC1TP53MAPTHTT
SCHEMBL8155174 0.78 EPHX2 (0.49) EPHX2NPC1MAPTRAB9ADDR1
SCHEMBL6293985 0.78 NPC1 (0.50) GPR27NPC1TP53MAPTNFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6841560-B2 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. (GB) 2005-01-11 US claimed
US-20030144320-A1 For treatment and/or prevention of anxiety, mania, depression, panic disorders, nerve sustem disorders SMITHKLINE BEECHAM P.L.C. 2003-07-31 US claimed
US-20010016657-A1 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. 2001-08-23 US claimed
US-6841560-B2 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. (GB) 2005-01-11 US disclosed
US-20040209912-A1 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. 2004-10-21 US disclosed
US-20030144320-A1 For treatment and/or prevention of anxiety, mania, depression, panic disorders, nerve sustem disorders SMITHKLINE BEECHAM P.L.C. 2003-07-31 US disclosed
US-20010016657-A1 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. 2001-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209912-A1 Substituted isoquinoline derivatives and their use as anticonvulsants INA, GRIN2C, GRIN2A EPHX2 897/4885TRPV4 434/4885GPR27 1070/4885
US-20010016657-A1 Substituted isoquinoline derivatives and their use as anticonvulsants INA, GRIN2C, GRIN2A EPHX2 897/4885TRPV4 434/4885GPR27 1070/4885
US-20030144320-A1 For treatment and/or prevention of anxiety, mania, depression, panic disorders, nerve sustem disorders PNMT, SLC6A2, GABBR1 EPHX2 2648/4885TRPV4 1266/4885GPR27 2193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.